50339-06-5

Upstream product

• 103432-67-3 1-methyl-3-t-butoxycarbonyl-1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one 
• 56291-51-1 2-amino-3-methylaminopyridine 
• 98961-03-6 (2-amino-[3]pyridyl)-methyl-carbamic acid ethyl ester 
• 5028-20-6 3-amino-2-methylaminopyridine 
• 13534-99-1 2-Amino-3-bromopyridine 
• 530-62-1 1,1'-carbonyldiimidazole 
• 1353677-72-1 N-benzyl-N-methyl-2-nitropyridin-3-amine 
• 54231-32-2 3-chloro-2-nitropyridine 
• 116708-48-6 3-cyclopenten-1-yl-1,3-dihydro-2H-imidazo<4,5-b>pyridin-2-one 
• 116708-36-2 7,8,9,10-tetrahydrocyclopentapyrido<3,2-b><1,4>diazepin-6(5H)-one 
• 452-58-4 2,3-Diaminopyridine 
• 116708-50-0 3-cyclopenten-1-yl-1,3-dihydro-1-methyl-2H-imidazo<4,5-b>pyridin-2-one 
• 75-44-5 phosgene 

Downstream Products

• 178885-60-4 2-amino-1-methylimidazo[4,5-b]pyridine 
• 1613148-98-3 3-[2-(5-methoxy-1-phenyl-1H-benzimidazol-2-yl)ethyl]-1-methyl-1,3-dihydro-2H-imidazo[4,5-b]pyridin-2-one 

Relevant academic research and scientific papers

SUBSTITUTED BENZIMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted benzimidazole carboxamides and related compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat a medical disorder, e.g., cancer, lysosomal storage disorder, neurodegenerative disorder, inflammatory disorder, in a patient.

Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase

In order to explore the interactions of bisphosphonate ligands with the active site and an allosteric pocket of the human farnesyl pyrophosphate synthase (hFPPS), substituted indole and azabenzimidazole bisphosphonates were designed as chameleon ligands. NMR and crystallographic studies revealed that these compounds can occupy both sub-pockets of the active site cavity, as well as the allosteric pocket of hFPPS in the presence of the enzyme's Mg2+ ion cofactor. These results are consistent with the previously proposed hypothesis that the allosteric pocket of hFPPS, located near the active site, plays a feed-back regulatory role for this enzyme.

CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS

There are described cydohexyl amide derivatives useful as corticotropin releasing factor (CRF) receptor antagonists

FUSED HETEROCYCLIC COMPOUNDS

The present invention provides a compound which has the effect of PDE inhibition, and which is useful as an agent for preventing or treating schizophrenia. The compound is represented by the formula (I): wherein the symbols are defined in the specification.